FINWIRES · TerminalLIVE
FINWIRES

Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate

By

Silexion Therapeutics (SLXN) said Wednesday it has initiated its phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, adding that the clinical site is now cleared to commence patient screening.

The trial will evaluate SIL204 in combination with standard-of-care chemotherapy. It is structured as an initial safety run-in group of 18 patients, followed by expansion into sites worldwide to obtain a randomized cohort of about 166 patients.

Shares of the company fell over 21% in recent Wednesday trading.

Price: $2.01, Change: $-0.54, Percent Change: -21.06%

Related Articles

Wire

Orion Q2 Adjusted Earnings Fall, Revenue Rises; Cuts 2026 EPS Guidance

Orion Group (ORN) reported Q2 adjusted earnings late Tuesday of $0.02 per share, down from $0.07 a year earlier.Analysts polled by FactSet expected $0.06.Revenue for the quarter ended June 30 rose to $221.9 million from $205.3 million a year earlier.Analysts expected $225.7 million.The company now expects 2026 adjusted EPS of $0.23 to $0.30, compared with $0.36 to $0.42 earlier. The company continues to see full-year revenue of $900 million to $950 million.Analysts expect $0.39 and $938.9 million, respectively.Shares of Orion were down 8% in after-hours activity.

$ORN
Wire

Rogers Q2 Adjusted Earnings, Revenue Rise

Rogers (ROG) reported Q2 adjusted earnings late Tuesday of $0.92 per diluted share, up from $0.34 a year earlier.Three analysts polled by FactSet expected $0.99.Revenue in the three months ended June 30 rose to $216.8 million from $202.8 million a year earlier.Three analysts surveyed by FactSet expected $215 million.The company expects Q3 adjusted EPS of $1.10 to $1.30 on revenue of $233 million to $243 million.Three analysts expect EPS of $1.03 on revenue of $225.5 million.The company's shares fell 2% in after-hours trading.

$ROG
Wire

Extra Space Storage Q2 Core FFO, Revenue Rise

Extra Space Storage (EXR) reported Q2 core funds from operations late Tuesday of $2.15 per diluted share, up from $2.05 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended June 30 rose to $874.2 million from $841.6 million a year earlier.Analysts expected $875 million.The company raised full-year core FFO guidance to $8.25 to $8.40 a share from the prior range of $8.05 to 8.35. Analysts expect $8.29.The company's shares fell 1.5% in after-hours trading.

$EXR